Skip Navigation

Clinical trial underscores promise of immunotherapy, in combination with second drug, for ovarian cancer

Panos A. Konstantinopoulos, MD, PhD
June 13, 2019
A combination of an immunotherapy drug and a DNA repair-blocking agent can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers indicates. The trial, known as...
Read Story
  • Explore the Newsroom

    News Releases

    See our news releases about cancer care, cancer research, and cancer treatment by Dana-Farber Cancer Institute doctors and researchers.

    News Coverage

    Get the latest news about Dana-Farber Cancer Institute.

    News Videos

    Watch brief explainer videos focusing on science, research, and advances in cancer, featuring Dana-Farber Cancer Institute doctors and researchers.

    For Journalists

    Dana-Farber welcomes the opportunity to partner with journalists. Find contacts, resources, and more.

    Publications

    Read the latest issues of Dana-Farber publications.

    Insight Blog

    Insight features the latest in cancer care and research news from Dana-Farber.

    Dana-Farber Spotlight

    Sign up to receive Dana-Farber Spotlight, our email newsletter.
    View the current issue
    Subscribe now
    Unsubscribe from mailings
  • View Our Events Calendar

    View Dana-Farber's calendar of events, including nutrition seminars, health and wellness classes, patient education, community outreach and fundraising events, and support groups.

    caregiver support group


    Participants in a caregiver support group